Wisconsin Institute For Immune And Cell Therapy Inc is located in Madison, WI. According to its NTEE Classification (H99) the organization is classified as: Medical Research N.E.C., under the broad grouping of Medical Research and related organizations. As of 12/2022, Wisconsin Institute For Immune And Cell Therapy Inc employed 4 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Wisconsin Institute For Immune And Cell Therapy Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Wisconsin Institute For Immune And Cell Therapy Inc generated $500.0k in total revenue. All expenses for the organization totaled $292.2k during the year ending 12/2022.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL.
Describe the Organization's Program Activity:
Part 3 - Line 4a
IN 2022, INCLUDING AN ORGANIZATIONAL PERIOD UNDER TREASURY SECTION 1.170A-9(D)(2)(IX) FOR A NEWLY CREATED MEDICAL RESEARCH ORGANIZATION, WIICT PERFORMED RESEARCH TO DESIGN AND MAKE MULTIPLE MRNAS, AND TO ANALYZE AND EVALUATE EACH FOR YIELD, PURITY, SIZE, NUCLEIC ACID SEQUENCE, CAP STRUCTURE, TAIL LENGTH, CONCENTRATION, POTENCY AND OTHER CHEMICAL, BIOCHEMICAL, AND PHYSICAL PROPERTIES, AND FOR EFFECTIVENESS FOR USE IN MANUFACTURING CELL THERAPIES FOR TREATMENT OF HUMAN PATIENTS WITH PRIMARY IMMUNE DEFICIENCY (PID) DISEASES CAUSED BY GENE MUTATIONS. WIICT PROVIDED OPTIMIZED VERSIONS OF MULTIPLE SAID MRNA TO ITS CLINICAL COLLABORATORS AT THE NIH CLINICAL CENTER IN BETHESDA, MD FOR THEIR USE IN CLINICAL RESEARCH IN HUMAN AND ANIMAL CELLS AND IN ANIMAL MODELS TO SELECT OPTIMAL MRNA CONSTRUCTS AND TO GENERATE CLINICAL DATA RELATED THERETO TO SUPPORT THE FILING AND IMPLEMENTATION OF AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR A PHASE I OR PHASE I/II HUMAN CLINICAL TRIAL FOR ONE OF THOSE PID DISEASES.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Gary A Dahl President And Director | OfficerTrustee | 1 | $0 |
Jerome J Jendrisak Vp, Secr./treas., Director | OfficerTrustee | 1 | $0 |
Kieran Coe Director | OfficerTrustee | 1 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $500,000 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $500,000 |
Total Program Service Revenue | $0 |
Investment income | $0 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $500,000 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $197,100 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $63,241 |
Payroll taxes | $17,004 |
Fees for services: Management | $0 |
Fees for services: Legal | $8,986 |
Fees for services: Accounting | $0 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $5,692 |
Advertising and promotion | $0 |
Office expenses | $48 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $0 |
Travel | $0 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $0 |
All other expenses | $44 |
Total functional expenses | $292,215 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $258,524 |
Savings and temporary cash investments | $5,000 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $1,977 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $265,501 |
Accounts payable and accrued expenses | $24,650 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $24,650 |
Net assets without donor restrictions | $0 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $65,000 |
Retained earnings, endowment, accumulated income, or other funds | $175,851 |
Total liabilities and net assets/fund balances | $265,501 |